References
- Almici C, Skert C, Verardi R et al (2014) Changes in circulating endothelial cells count could become a valuable tool in the diagnostic definition of acute graft-versus-host disease. Transplantation 98:706–712.
https://doi.org/10.1097/tp.0000000000000385 - Asherie N, Kfir-Erenfeld S, Avni B et al (2023) Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial. Haematologica 108:1827–1839.
https://doi.org/10.3324/haematol.2022.281628 -
Biedermann BC, Sahner S, Gregor M et al (2002) Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 359:2078–2083.
https://doi.org/10.1016/s0140-6736(02)08907-9 BiedermannBC SahnerS GregorM 2002 Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease Lancet 359 2078 2083https://doi.org/10.1016/s0140-6736(02)08907-9 - Cordes S, Mokhtari Z, Bartosova M et al (2021) Endothelial damage and dysfunction in acute graft-versus-host disease. Haematologica 106:2147–2160.
https://doi.org/10.3324/haematol.2020.253716 - Eelen G, de Zeeuw P, Treps L et al (2018) Endothelial cell metabolism. Physiol Rev 98:3–58.
https://doi.org/10.1152/physrev.00001.2017 - Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31.
https://doi.org/10.1038/nm0195-27 - Greenbaum U, Strati P, Saliba RM et al (2020) The EASIX (Endothelial Activation and Stress Index) score predicts for CAR T related toxicity in patients receiving axicabtagene ciloleucel (axi-cel) for non-Hodgkin lymphoma (NHL). Blood 136(Supplement 1):-17–18.
https://doi.org/10.1182/blood-2020-141388 - Greenbaum U, Strati P, Saliba RM et al (2021) CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5:2799–2806.
https://doi.org/10.1182/bloodadvances.2021004575 - Gust J, Ponce R, Liles WC et al (2020) Cytokines in CAR T cell-associated neurotoxicity. Front Immunol 11:577027.
https://doi.org/10.3389/fimmu.2020.577027 - Hay KA, Hanafi LA, Li D et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy. Blood 130:2295–2306.
https://doi.org/10.1182/blood-2017-06-793141 - Korell F, Penack O, Mattie M et al (2022) EASIX and severe endothelial complications after CD19-directed CAR-T cell therapy-a cohort study. Front Immunol 13:877477.
https://doi.org/10.3389/fimmu.2022.877477 - Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25:625–638.
https://doi.org/10.1016/j.bbmt.2018.12.758 - Lee J, Upreti HV, Sannareddy A et al (2024) Pre-lymphodepletion Endothelial Activation and Stress Index as a predictor of clinical outcomes in B-cell maturation antigen CAR T therapy for multiple myeloma. Transplantat Cell Ther 30(Supplement):S221–S222.
https://doi.org/10.1016/j.jtct.2023.12.288 -
Luft T, Benner A, Jodele S et al (2017) EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematol 4:e414–e423.
https://doi.org/10.1016/s2352-3026(17)30108-4 LuftT BennerA JodeleS 2017 EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis Lancet Haematol 4 e414 e423https://doi.org/10.1016/s2352-3026(17)30108-4 - Luft T, Benner A, Terzer T et al (2020) EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplant 55:553–561.
https://doi.org/10.1038/s41409-019-0703-1 - Mariotti J, Magri F, Giordano L et al (2023) EASIX predicts non-relapse mortality after haploidentical transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant 58:247–256.
https://doi.org/10.1038/s41409-022-01874-5 - Menzel L, Höpken UE, Rehm A (2020) Angiogenesis in lymph nodes is a critical regulator of immune response and lymphoma growth (Review). Front Immunol 11:591741.
https://doi.org/10.3389/fimmu.2020.591741 - Merz A, Germing U, Kobbe G et al (2019) EASIX for prediction of survival in lower-risk myelodysplastic syndromes. Blood Cancer J 9:85.
https://doi.org/10.1038/s41408-019-0247-z - Molema G (2010) Heterogeneity in endothelial responsiveness to cytokines, molecular causes, and pharmacological consequences. Semin Thromb Hemost 36:246–264.
https://doi.org/10.1055/s-0030-1253448 - Page AV, Liles WC (2013) Biomarkers of endothelial activation/dys-function in infectious diseases. Virulence 4:507–516.
https://doi.org/10.4161/viru.24530 - Palomo M, Diaz-Ricart M, Carbo C et al (2010) Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. Biol Blood Marrow Transplant 16:985–993.
https://doi.org/10.1016/j.bbmt.2010.02.008 - Park S, Go SI, Lee GW (2022) The Endothelial Activation and Stress Index (EASIX) score is an independent prognostic factor in patients with diffuse large B-cell lymphoma. BMC Cancer 22:816.
https://doi.org/10.1186/s12885-022-09915-4 - Penack O, Henke E, Suh D et al (2010) Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. J Natl Cancer Inst 102:894–908.
https://doi.org/10.1093/jnci/djq172 - Pennisi M, Sanchez-Escamilla M, Flynn JR et al (2021) Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv 5: 3397–3406.
https://doi.org/10.1182/bloodadvances.2020003885 - Rajendran P, Rengarajan T, Thangavel J et al (2013) The vascular endothelium and human diseases. Int J Biol Sci 9:1057–1069.
https://doi.org/10.7150/ijbs.7502 - Riesner K, Shi Y, Jacobi A et al (2017) Initiation of acute graft-versus-host disease by angiogenesis. Blood 129:2021–2032.
https://doi.org/10.1182/blood-2016-08-736314 - Sidana S, Hosoya H, Jensen A et al (2023) Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. Blood Cancer J 13:158.
https://doi.org/10.1038/s41408-023-00929-0 - Song GY, Jung SH, Kim K et al (2020) Endothelial Activation and Stress Index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma. BMC Cancer 20:803.
https://doi.org/10.1186/s12885-020-07317-y - Thanhakun R, Wudhikarn K, Bunworasate U et al (2023) Endothelial Activation and Stress Index as a prognostic factor of diffuse large B-cell lymphoma: the report from the nationwide multi-center Thai Lymphoma Study Group. Ann Hematol 102:3533–3541.
https://doi.org/10.1007/s00277-023-05437-6 - Tomasik J, Drozd-Sokołowska J, Kacprzyk P et al (2023) Tisagenlecleucel CAR-T for relapsed/refractory diffuse large B-cell lymphoma, one therapy; two different clinical presentations. An urgent need to design adverse event predictors. Acta Haematologica Polonica 54:100–103.
https://doi.org/10.5603/AHP.a2023.0018 - Trepels T, Zeiher AM, Fichtlscherer S (2006) The endothelium and inflammation. Endothelium 13:423–429.
https://doi.org/10.1080/10623320601061862 - von Elm E, Altman DG, Egger M et al (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61:344–349.
https://doi.org/10.1016/j.jclinepi.2007.11.008 - Zhang X, Zhu L, Zhang H et al (2022) CAR-T cell therapy in hemato-logical malignancies: current opportunities and challenges. Front Immunol 13:927153.
https://doi.org/10.3389/fimmu.2022.927153